Compare Stocks: BDRX, KTTA, GDTC, and VTGN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$1.57 -2.2%	$2.45	$1.02 ▼ $59.40	$3.13M	1.24	391,067 shs	17,782 shs
GDTC CytoMed Therapeutics	$0.83 +3.2%	$1.01	$0.68 ▼ $3.68	$9.77M	0.04	271,002 shs	2,449 shs
KTTA Pasithea Therapeutics	$0.48 +0.6%	$0.51	$0.28 ▼ $2.06	$15.94M	0.29	528,065 shs	23,933 shs
VTGN VistaGen Therapeutics	$0.27 +0.8%	$0.40	$0.20 ▼ $5.14	$11.85M	0.41	2.23 million shs	926,414 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	+3.90%	+12.68%	-35.74%	-57.89%	-95.51%
GDTC CytoMed Therapeutics	-3.83%	-12.96%	-22.32%	+3.99%	-56.98%
KTTA Pasithea Therapeutics	-6.45%	+6.14%	-3.74%	-39.24%	-30.50%
VTGN VistaGen Therapeutics	-8.28%	+7.67%	+2.25%	-57.56%	-91.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BDRX Biodexa Pharmaceuticals	$1.57 -2.2%	$2.45	$1.02 ▼ $59.40	$3.13M	1.24	391,067 shs	17,782 shs
GDTC CytoMed Therapeutics	$0.83 +3.2%	$1.01	$0.68 ▼ $3.68	$9.77M	0.04	271,002 shs	2,449 shs
KTTA Pasithea Therapeutics	$0.48 +0.6%	$0.51	$0.28 ▼ $2.06	$15.94M	0.29	528,065 shs	23,933 shs
VTGN VistaGen Therapeutics	$0.27 +0.8%	$0.40	$0.20 ▼ $5.14	$11.85M	0.41	2.23 million shs	926,414 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BDRX Biodexa Pharmaceuticals	+3.90%	+12.68%	-35.74%	-57.89%	-95.51%
GDTC CytoMed Therapeutics	-3.83%	-12.96%	-22.32%	+3.99%	-56.98%
KTTA Pasithea Therapeutics	-6.45%	+6.14%	-3.74%	-39.24%	-30.50%
VTGN VistaGen Therapeutics	-8.28%	+7.67%	+2.25%	-57.56%	-91.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BDRX Biodexa Pharmaceuticals	1.00	Sell	N/A	N/A
GDTC CytoMed Therapeutics	1.00	Sell	N/A	N/A
KTTA Pasithea Therapeutics	2.67	Moderate Buy	$3.00	528.93% Upside
VTGN VistaGen Therapeutics	1.80	Reduce	$0.95	257.14% Upside

Current Analyst Ratings Breakdown

Latest BDRX, KTTA, GDTC, and VTGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/17/2026	KTTA Pasithea Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/8/2026	GDTC CytoMed Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/24/2026	KTTA Pasithea Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/18/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
6/16/2026	KTTA Pasithea Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
6/3/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
6/3/2026	VTGN VistaGen Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/1/2026	KTTA Pasithea Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
5/13/2026	BDRX Biodexa Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BDRX Biodexa Pharmaceuticals	$470K	6.66	N/A	N/A	$110.30 per share	0.01
GDTC CytoMed Therapeutics	$250K	39.09	N/A	N/A	$0.45 per share	1.84
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$2.39 per share	N/A
VTGN VistaGen Therapeutics	$1.27M	9.30	N/A	N/A	$0.90 per share	0.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BDRX Biodexa Pharmaceuticals	-$8.42M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/11/2026 (Estimated)
GDTC CytoMed Therapeutics	-$3.10M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	-$20.43M	-$2.08	N/A	N/A	N/A	N/A	-57.44%	-53.61%	8/13/2026 (Estimated)
VTGN VistaGen Therapeutics	-$69.68M	-$1.83	N/A	N/A	N/A	-5,487.01%	-133.02%	-105.79%	N/A

Latest BDRX, KTTA, GDTC, and VTGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	KTTA Pasithea Therapeutics	-$0.16	N/A	N/A	N/A	$0.30 million	N/A
6/15/2026	Q4 2026	VTGN VistaGen Therapeutics	-$0.3367	-$0.37	-$0.0333	-$0.37	$0.40 million	$0.47 million
5/15/2026	Q1 2026	KTTA Pasithea Therapeutics	-$0.45	-$0.12	+$0.33	-$0.12	$0.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GDTC CytoMed Therapeutics	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
VTGN VistaGen Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BDRX Biodexa Pharmaceuticals	N/A	2.03	2.03
GDTC CytoMed Therapeutics	0.06	5.17	5.17
KTTA Pasithea Therapeutics	N/A	35.41	35.41
VTGN VistaGen Therapeutics	N/A	3.67	3.67

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BDRX Biodexa Pharmaceuticals	17.51%
GDTC CytoMed Therapeutics	0.04%
KTTA Pasithea Therapeutics	23.92%
VTGN VistaGen Therapeutics	78.39%

Insider Ownership

Company	Insider Ownership
BDRX Biodexa Pharmaceuticals	0.34%
GDTC CytoMed Therapeutics	N/A
KTTA Pasithea Therapeutics	2.00%
VTGN VistaGen Therapeutics	2.93%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BDRX Biodexa Pharmaceuticals	20	2.00 million	1.99 million	Not Optionable
GDTC CytoMed Therapeutics	N/A	11.83 million	N/A	Not Optionable
KTTA Pasithea Therapeutics	3	33.41 million	32.75 million	Not Optionable
VTGN VistaGen Therapeutics	40	44.38 million	43.08 million	Optionable

BDRX, KTTA, GDTC, and VTGN Headlines

Recent News About These Companies

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

August 6, 2026 | globenewswire.com

SRX Global (NYSE American: SRXH) Acquires Stake in Vistagen Therapeutics

August 4, 2026 | markets.businessinsider.com

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives $0.95 Average Price Target from Brokerages

August 4, 2026 | americanbankingnews.com

Vistagen Appoints Douglas J. Williamson to its Board of Directors

July 31, 2026 | globenewswire.com

Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)

July 18, 2026 | theglobeandmail.com

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

July 15, 2026 | insidermonkey.com

VistaGen Therapeutics (VTGN) Receives a Rating Update from a Top Analyst

July 4, 2026 | theglobeandmail.com

Vistagen Therapeutics, Inc. (VTGN) Discusses PALISADE-4 Phase III Results and Post-Hoc Analyses in Social Anxiety Disorder Transcript

June 30, 2026 | seekingalpha.com

Vistagen's anxiety disorder drug misses main goal in late-stage trial, shares plummet

June 30, 2026 | reuters.com

Vistagen Therapeutics’ 2026 Workforce Cuts Raise Execution Risks and Threaten Long-Term Growth

June 17, 2026 | tipranks.com

Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

June 15, 2026 | businesswire.com

Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder

June 9, 2026 | businesswire.com

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

June 1, 2026 | prnewswire.com

Vistagen Appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer

May 19, 2026 | businesswire.com

Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?

May 19, 2026 | insidermonkey.com

Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

May 12, 2026 | businesswire.com

Vistagen Announces Completion of Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

May 8, 2026 | businesswire.com

Kuehn Law Encourages Investors of Vistagen Therapeutics, Inc. to Contact Law Firm

April 29, 2026 | globenewswire.com

Vistagen Therapeutics, Inc. (NASDAQ: VTGN) Investor Alert: Schubert Jonckheer Investigating Possible False Claims Regarding Drug Candidate Following 80% Stock Drop

April 28, 2026 | prnewswire.com

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

April 22, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, KTTA, GDTC, and VTGN Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

$1.56 -0.04 (-2.19%)

As of 02:01 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

CytoMed Therapeutics NASDAQ:GDTC

$0.83 +0.03 (+3.24%)

As of 01:04 PM Eastern

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.

Pasithea Therapeutics NASDAQ:KTTA

$0.48 +0.00 (+0.63%)

As of 02:02 PM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

VistaGen Therapeutics NASDAQ:VTGN

$0.27 +0.00 (+0.83%)

As of 02:03 PM Eastern

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, KTTA, GDTC, and VTGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, KTTA, GDTC, and VTGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, KTTA, GDTC, and VTGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, KTTA, GDTC, and VTGN Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

CytoMed Therapeutics NASDAQ:GDTC

Pasithea Therapeutics NASDAQ:KTTA

VistaGen Therapeutics NASDAQ:VTGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BDRX, KTTA, GDTC, and VTGN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BDRX, KTTA, GDTC, and VTGN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BDRX, KTTA, GDTC, and VTGN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BDRX, KTTA, GDTC, and VTGN Company Descriptions

Biodexa Pharmaceuticals NASDAQ:BDRX

CytoMed Therapeutics NASDAQ:GDTC

Pasithea Therapeutics NASDAQ:KTTA

VistaGen Therapeutics NASDAQ:VTGN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools